Minos Biosciences

A spin-off from ESPCI Paris - PSL, Minos Biosciences aims at becoming a prominent player in the fast growing cell analysis market by providing an enabling solution that brings a new dimension to single-cell analysis (a must-have in every lab). Minos Biosciences comprises a passionate team willing to bring to pharma/biotech and academic research its new technology, that will have an enormous beneficial impact on the understanding of complex diseases (notably cancer) and drug resistance mechanisms, the discovery of new targets & drugs, biomarkers for personalised medicine, and in the longer term in the diagnostics field.

Also single-cell omics by barcoded next-generation sequencing (NGS) have enabled considerable progress in the understanding of biological mechanisms at the molecular level, the heterogeneity in clinical responses, for example to current cancer treatments, highlights biological unknowns that require further exploration and new techniques. Life-science researchers and clinicians urgently need innovative, fast and cost-effective solutions to gain a better understanding of complex biological systems. In particular, currently no approach allows the dynamic observation of cell plasticity, cell-cell or host-pathogen interaction, while giving access to the underlying transcriptomic profiles.

Minos Biosciences aims to uncover the full picture of cell diversity and dynamics in heterogeneous tissues. By correlating dynamic functional assays with phenotypic and multi-omic profiling, our solution is a paradigm shift in single-cell analysis. 

This novel approach has the potential to improve knowledge, for example, about (i) cancer by connecting genetic and non-genetic factors, cellular plasticity and cellular environment, but also about (ii) autoimmune diseases by understanding the complex role of immune cells at the multi-omic and phenotypic levels, or about (iii) infectious diseases by correlating host-pathogen interaction to genetic and epigenetic variations.

Ultimately, Minos Biosciences will pave the way for the discovery of new therapeutic targets or biomarkers, and the development of new therapeutic strategies for precision medicine, notably cell therapies.

With the launch of our solution in 2026, our goal is to have more than 1,200 systems installed by the end of 2031, mainly in European and American laboratories, and to have sold more than 60,000 kits, resulting in the production of data with very high scientific and biomedical value.

Simultaneously, Minos will deploy a strategy of collaborations with pharmaceutical/biotech companies, to help them accelerate the discovery and development of new treatments and/or biomarkers for precision medicine. Through these partnerships, we also plan to expand the range of assays we develop and commercialise.

In the longer-term, Minos will ensure sustained growth along two strategic axes:

• Expanding our products by exploiting the additional patent applications exclusively licensed to Minos, including spatial omics methods, and molecular systems for signal amplification that will unlock important new applications for Minos’s core technology.
• Addressing diagnostic markets, although this will probably require the development of a simplified version of the technology and addressing regulatory issues.